Report Sections

See All Reports

  • HP:0000726: Dementia
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0000726: Dementia

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (6)


    Name (Synonyms) Correlation
    drug3289 Telephone interview Wiki 0.71
    drug578 COVID WHELD Wiki 0.71
    drug1417 High Intensity Interval Training group Wiki 0.71
    Name (Synonyms) Correlation
    drug3633 Yoga group Wiki 0.71
    drug810 Combination Wiki 0.71
    drug3218 Survey Wiki 0.18

    Correlated MeSH Terms (2)


    Name (Synonyms) Correlation
    D003704 Dementia NIH 1.00
    D060825 Cognitive Dysfunction NIH 0.24

    Correlated HPO Terms (1)


    Name (Synonyms) Correlation
    HP:0001268 Mental deterioration HPO 0.24

    Clinical Trials

    Navigate: Correlations   HPO

    There are 2 clinical trials


    1 Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia

    Coronavirus disease 2019 has forced worldwide the implementation of unprecedented restrictions to control its rapid spread and mitigate its impact. The Spanish government has enforced social distancing, quarantine and home confinement. This restriction of daily life activities and separation from loved ones may lead to social isolation and loneliness with health-related consequences in community-dwelling older adults with mild cognitive impairment or mild dementia and their caregivers. Additionally, an inadequate access to healthcare and social support services may aggravate chronic conditions. Technology home-based interventions emerge for combating social isolation and loneliness preventing the risk of viral exposure. The aim of this multicentre cohort study is to explore, analyze and determine the impact of social isolation on: 1) cognition, quality of life, mood, technophilia and perceived stress of community-dwelling older adults with mild cognitive impairment or mild dementia, and on caregiver burden; 2) health and social care services access and utilization, and 3) cognitive, social and entertainment use of ICTs. This study will be conducted in two Spanish regions Andalucía (Málaga) and Cataluña (Tarrasa). In total 200 dyads, consisting of a person with mild cognitive impairment or mild dementia (PMCI/MD) and their informal caregiver will be contacted by telephone. Potential respondents will be participants of the SMART 4 MD (N=100) and TV-AssistDem (N=100) clinical trials. The change in means in the variables will be analyzed comparing baseline results in the previous studies with those during and after confinement using the ANOVA test of repeated measures or the non-parametric Friedman test if appropriate. The performance of a multivariate analysis of variance (ANCOVA) to introduce possible covariates will also be contemplated. A 95% confidence level will be used.

    NCT04385797
    Conditions
    1. Mild Cognitive Impairment
    2. Dementia
    Interventions
    1. Other: Telephone interview
    MeSH:Dementia Cognitive Dysfunction
    HPO:Cognitive impairment Dementia Mental deterioration

    Primary Outcomes

    Description: The Mini-Mental State Examination (MMSE) (23) will be used to assess the cognitive function of the PMCI/MD. The most common cutoff scores for cognitive impairment and dementia are ranging 23 to 27 over 30. As telephone call interviewing will be the safest means to communicate with the PMCI/MD during and after the COVID-19 pandemic the 22 items telephone version of the MMSE will be used (24). All points of the MMSE can be covered in the telephone version except the last section assessing language and motor skills. In the phone version, we will ask the subject to repeat a phrase and name one item (For example: "Tell me, what is the name of the object you are using to talk to me?"). However, a second item will be not be named, nor will be the person be asked to follow a three-stage command, read and obey a sentence, write a sentence, or copy an intersecting pentagon as in the original version.

    Measure: Change on cognitive function in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Secondary Outcomes

    Description: The Quality of Life-Alzheimer's Disease Scale (QoL-AD) (19-22) is an instrument specifically designed to measure QoL in PMCI/MD from the perspective of both the patient and the informal caregiver. It is a 13-item measure, which includes assessments of the person´s relationships with friends and family, financial situation, physical condition, mood, memory, and an overall assessment of life quality. Response are 4-point multiple choice options (1 = poor, 2= fair, 3= good, 4 = excellent). Scale scores range from 13 to 52, with higher scores indicating greater quality of life. When cognitive function may be compromised, informal caregivers will complete the QoL-AD, on behalf of the PMCI/MD.

    Measure: Change on quality of life in Alzheimer´s Disease in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The European Quality of Life 5 Dimensions 3 Levels (EuroQoL-5D-3L) is a standardized generic instrument consisting of a descriptive system and a visual analogue scale (VAS). The descriptive system comprises 5 dimensions covering mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, moderate problems and extreme problems. A 1-digit number expresses the level selected for that dimension. The digits can be combined into a 5-digit number that describes the patient's health state. The VAS records the patient's self-rated health on a vertical scale, where the endpoints are 100 = 'The best health you can imagine' and 0 = 'The worst health you can imagine'. EuroQoL-5D-3L has been shown to correlate well with QoL-AD, indicating that using both measures side-by-side is compatible.

    Measure: Change on quality of life in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Short Form of the Geriatric Depression Scale (GDS) (25) will be used to assess mood. Of the 15 items, 10 indicate depression when answered positively, while the rest (1, 5, 7, 11, 13) when answered negatively. Scores of 0-4 are considered normal, 5-8 indicate mild depression, 9-11 moderate depression, and 12-15 severe depression.

    Measure: Change on mood in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Instrument for Measuring Older People's Attitudes Toward Technology (TechPH) measures older people's attitudes and enthusiasm for health technology (26). This instrument refers to technophilia as a person's enthusiasm for and positive feelings toward their technology use and absence of the fears and doubts some older people could have about their ability to manage using new technology. The six items of the instrument measure two factors of technophilia: 3 items concerning techEnthusiasm and 3 items techAnxiety. Response are constructed with a five-point Likert scale questionnaire, ranging from 1 (fully disagree) to 5 (fully agree).

    Measure: Change on technophilia in people with mild cognitive impairment or mild dementia prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Perceived Stress Scale (PSS) measures the degree to which situations in one's life are appraised as stressful. The scale has 10 questions regarding feelings and thoughts during the last month and are rated according to frecuency 0 = Never 1 = Almost Never 2 = Sometimes 3 = Fairly Often 4 = Very Often. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the four positively stated items (items 4, 5, 7, & 8) and then summing across all scale items

    Measure: Change on perceived stress in people with mild cognitive impairment or mild dementia during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Zarit Burden Interview (ZBI-12) is a 12-item scale with each answer chosen from a 5-point Likert scale (Nearly always=4, Quite frequently=3, Sometimes=2, Rarely=1, Never=0). It is a shortened version of the original scale, was developed specifically for informal caregivers of PMCI/MD and covers issues such as caregiver stress and the degree to which caring is affecting their health and social life. Total score range 0 to 48 (0-10= no to mild burden, 10-20= mild to moderate burden >20= high burden).

    Measure: Change on caregiver burden prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: The Client Service Receipt Inventory (CSRI) (32,33) scale will be used to evaluate the service utilization. This scale is an internationally used method for gathering data on service utilization and other domains relevant for economic analysis of mental health care. It has five sections: background client information, accommodation and living situation, employment history, earnings and benefits, a record of services usually used and information about informal caregiver support. The sections assessed will be consultations, admissions and visits, grouped into subsections according to hospital, specialist, primary or home care. Treatment related to hospital admissions or illness exacerbation will also be assessed. It´s adaptability ensures it is compatible with the research aims, context, participants' likely circumstances, and the quantity and precision of information required.

    Measure: Change on healthcare and social support services access prior to, during and after confinement.

    Time: Through study completion, an average of 6 months

    Description: Use of ICTs (SmartPhone, Tablet, Computer, Smart-TV, or other) to contact healthcare and social support services, to stimulate cognition, to facilitate social connectedness (telephone call, video call, texting...), to access COVID-19 information and to enable entertainment.

    Measure: Change from health, cognitive, social, informative and entertainment related uses of ICT during and after confinement.

    Time: Through study completion, an average of 6 months
    2 Evidence-Based Supported Digital Intervention for Improving Wellbeing and Health of People Living in Care Homes and Care Home Staff (WHELD) During COVID-19: An RCT to Evaluate COVID-19 Adapted E-WHELD: Benefits and Cost-Effectiveness

    More than 400,000 people in the UK live in care homes. These individuals are particularly vulnerable to COVID-19; many are frail and the majority have concurrent physical health problems and dementia. This group are at the highest risk of becoming severely ill with COVID-19 and are dependent on a stretched care workforce. The isolation, together with the stresses and distressing nature of the current work environment is also likely to have an impact on the mental health and well-being of care staff. It is vital to provide good quality support to enable care staff to remain resilient, and to enable good quality care that maintains the well-being of residents with dementia and reduces emerging neuropsychiatric symptoms in residents without increasing harmful sedative medications. COVID E-WHELD is based on the optimized WHELD training intervention on successfully completed in randomised clinical trials (RCTs) in 86 care homes, more than 1000 people with dementia. WHELD reduced use of anti-psychotics, improved agitation and overall neuropsychiatric symptoms, improved quality of life and reduced mortality for people with dementia. A digital version of WHELD (eWHELD) with virtual supervision in a further care home RCT including 130 people with dementia has demonstrated benefits for staff carers and improvements in the quality of life of people with dementia, with eWHELD combined with virtual supervision, but not with e-learning alone. The current project will evaluate a COVID-19 adapted version of eWHELD to address current needs of care homes during the COVID-19 pandemic. This will be undertaken in a 2 arm, 4 month, randomized cluster RCT in 1280 care homes (allowing for 75% drop out with COVID-19 outbreaks) to determine whether COVID-19 adapted eWHELD improves quality of life and mental health for people with dementia in care homes and the mental health of care staff.

    NCT04590469
    Conditions
    1. Dementia
    Interventions
    1. Other: COVID WHELD
    MeSH:Dementia
    HPO:Dementia

    Primary Outcomes

    Description: Validated quality of life measure for people with dementia, assessed by informant interview. Minimum score = 32 Maximum score = 128; Higher score denotes better outcome.

    Measure: Dementia Quality of Life - DEMQOL proxy

    Time: 4 months

    Secondary Outcomes

    Description: Standardized assessment of neuropsychiatric symptoms in people with dementia, assessed by informant interview. Minimum score = 0 Maximum score = 144; Higher score denotes worse outcome.

    Measure: Neuropsychiatric Inventory

    Time: 4 months

    Description: Use of antipsychotic and other psychotropic medications from prescribing charts

    Measure: Psychotropic medications

    Time: 4 months

    Description: Staff confidence measure, self completed questionnaire. Minimum score = 9 Maximum score = 45; Higher score denotes better outcome.

    Measure: Confidence in Dementia (CODE) Scale

    Time: 4 months

    Description: Perceived self efficacy of care staff, self completed questionnaire. Minimum score = 17 Maximum score = 68; Higher score denotes better outcome.

    Measure: Sense of Competence in Dementia Care Staff (SCIDS) scale

    Time: 4 months

    Description: Mental Health of care staff, self reported questionnaire. Minimum score = 0 Maximum score = 27; Higher score denotes worse outcome.

    Measure: Patient Health Questionnaire (PHQ-9)

    Time: 4 months

    Description: A standardized instrument for measuring generic health related quality of life, used for Health economic evaluation. Visual Analogue scale minimum score = 0, maximum score = 100. Higher score denotes better outcome.

    Measure: EQ5D (Euroquol 5D - 5 dimensions)

    Time: 4 months

    Description: to collect service utilization data for health economics. Assesses cost of service provision; as such no min/max values. Higher value denotes worse cost outcome.

    Measure: Client Service Receipt Inventory

    Time: 4 months

    Other Outcomes

    Description: Ordinal scale to rate progress towards personalized goals for people with dementia as a process outcome. Scale for each goal: Minimum score = 1 Maximum score = 4; Higher score denotes better outcome.

    Measure: Goal Attainment Scaling

    Time: 4 months

    HPO Nodes


    HP:0000726: Dementia
    Genes 293
    CHMP2B PPP2R2B WDR45 NOTCH2NLC NDP ALDH18A1 ND6 TUBA4A DNAJC13 TRNL1 TRNK SQSTM1 VPS35 PNPLA6 SORL1 TRNC HNRNPA2B1 SLC13A5 HFE NHLRC1 SNCA DGUOK COL4A1 CHMP2B APP RRM2B TRNS2 TARDBP NR4A2 POLG PRNP GRN APP ATP13A2 MAPT MAPT TTR GBA AARS2 MAPT TRPM7 ITM2B ATXN10 ND1 KCTD7 ATP6V1A TMEM106B IRF6 ATXN8OS CFAP43 C9ORF72 CSTB VPS13A ATP6 ATP13A2 LRRK2 ATXN2 PSAP MAPT TARDBP PRDX1 FMR1 GBA PODXL TBK1 VPS13C DCTN1 SDHB ROGDI GBA2 GCDH SNCA TBK1 NOTCH3 XPR1 SQSTM1 CYP27A1 TREX1 ATP7B MAPT COX1 TIMM8A TYROBP PRKAR1B ATN1 HTRA2 SPAST VCP ND6 PSEN1 SPG21 LRRK2 ATP13A2 PPP2R2B MMACHC ATP6V0A2 C9ORF72 DNMT1 GBE1 UBQLN2 PANK2 PSEN1 ATP6 SDHAF1 FTL OPA1 TRNQ TRNW MAPT C9ORF72 TMEM106B NOTCH2NLC RAB39B CISD2 DNAJC5 SNCA ALDH18A1 GBA MPO VCP COX2 SERPINI1 CLN3 PDGFRB TRNW CST3 PARK7 ATP6V1E1 GRN GRN ITM2B SYNJ1 COX3 EIF4G1 CHMP2B LRRK2 CERS1 ROGDI ADA2 MATR3 PRDM8 SNCA MAPT RNF216 TRNE GBA SCARB2 ABCA7 PSEN2 ADH1C WFS1 PRNP PSEN1 SDHD RNF216 APOE TRNS1 GIGYF2 TRNH APTX DLAT ABCD1 COX1 CSF1R PRNP FMR1 TREM2 ATXN2 ATXN2 ARSA FTL GLUD2 HTT TBP MATR3 DNM1L WDR45 PRICKLE1 PDGFB PRNP APP FBXO7 HEXA PSEN1 ND1 VCP ND4 TRNF TWNK AUH MBTPS2 APP PANK2 TRNV TRNQ APP TOMM40 PRNP HTRA1 ATP13A2 DNMT1 TRNS1 PSEN1 COX2 A2M HTT FUS ERCC8 HNRNPA2B1 HTRA1 MECP2 NOTCH3 MAPT CHMP2B CTSF CYTB C9ORF72 TREM2 ND5 CHMP2B ATXN3 MMACHC CLN6 VCP NPC1 CUBN PSEN2 GBA2 SNCB GBA POLG TRNL1 PRNP GRN HNRNPA1 ZFYVE26 LYST APP SNCAIP ATN1 TRNF VPS13C NPC2 NHLRC1 VCP TMEM106B CP ND5 TBP TUBB4A SQSTM1 EPM2A TRNS2 PRNP PSEN1 APOE TREM2 TREM2 PINK1 PLA2G6 TREM2 CHCHD10 PSEN1 EPM2A GM2A TYROBP PINK1 C9ORF72 WFS1 TYMP VCP ASAH1 DCTN1 PLAU SNCA DNAJC6 PLA2G6 TREM2 MAPT NOS3 COX3 SNCA HLA-DQB1 JPH3 C19ORF12 JPH3 PRKN ERCC4 APP UCHL1 CHCHD10 SPG21 SDHA
    Protein Mutations 1
    V158M
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0000726: Dementia
    Genes 293
    CHMP2B PPP2R2B WDR45 NOTCH2NLC NDP ALDH18A1 ND6 TUBA4A DNAJC13 TRNL1 TRNK SQSTM1 VPS35 PNPLA6 SORL1 TRNC HNRNPA2B1 SLC13A5 HFE NHLRC1 SNCA DGUOK COL4A1 CHMP2B APP RRM2B TRNS2 TARDBP NR4A2 POLG PRNP GRN APP ATP13A2 MAPT MAPT TTR GBA AARS2 MAPT TRPM7 ITM2B ATXN10 ND1 KCTD7 ATP6V1A TMEM106B IRF6 ATXN8OS CFAP43 C9ORF72 CSTB VPS13A ATP6 ATP13A2 LRRK2 ATXN2 PSAP MAPT TARDBP PRDX1 FMR1 GBA PODXL TBK1 VPS13C DCTN1 SDHB ROGDI GBA2 GCDH SNCA TBK1 NOTCH3 XPR1 SQSTM1 CYP27A1 TREX1 ATP7B MAPT COX1 TIMM8A TYROBP PRKAR1B ATN1 HTRA2 SPAST VCP ND6 PSEN1 SPG21 LRRK2 ATP13A2 PPP2R2B MMACHC ATP6V0A2 C9ORF72 DNMT1 GBE1 UBQLN2 PANK2 PSEN1 ATP6 SDHAF1 FTL OPA1 TRNQ TRNW MAPT C9ORF72 TMEM106B NOTCH2NLC RAB39B CISD2 DNAJC5 SNCA ALDH18A1 GBA MPO VCP COX2 SERPINI1 CLN3 PDGFRB TRNW CST3 PARK7 ATP6V1E1 GRN GRN ITM2B SYNJ1 COX3 EIF4G1 CHMP2B LRRK2 CERS1 ROGDI ADA2 MATR3 PRDM8 SNCA MAPT RNF216 TRNE GBA SCARB2 ABCA7 PSEN2 ADH1C WFS1 PRNP PSEN1 SDHD RNF216 APOE TRNS1 GIGYF2 TRNH APTX DLAT ABCD1 COX1 CSF1R PRNP FMR1 TREM2 ATXN2 ATXN2 ARSA FTL GLUD2 HTT TBP MATR3 DNM1L WDR45 PRICKLE1 PDGFB PRNP APP FBXO7 HEXA PSEN1 ND1 VCP ND4 TRNF TWNK AUH MBTPS2 APP PANK2 TRNV TRNQ APP TOMM40 PRNP HTRA1 ATP13A2 DNMT1 TRNS1 PSEN1 COX2 A2M HTT FUS ERCC8 HNRNPA2B1 HTRA1 MECP2 NOTCH3 MAPT CHMP2B CTSF CYTB C9ORF72 TREM2 ND5 CHMP2B ATXN3 MMACHC CLN6 VCP NPC1 CUBN PSEN2 GBA2 SNCB GBA POLG TRNL1 PRNP GRN HNRNPA1 ZFYVE26 LYST APP SNCAIP ATN1 TRNF VPS13C NPC2 NHLRC1 VCP TMEM106B CP ND5 TBP TUBB4A SQSTM1 EPM2A TRNS2 PRNP PSEN1 APOE TREM2 TREM2 PINK1 PLA2G6 TREM2 CHCHD10 PSEN1 EPM2A GM2A TYROBP PINK1 C9ORF72 WFS1 TYMP VCP ASAH1 DCTN1 PLAU SNCA DNAJC6 PLA2G6 TREM2 MAPT NOS3 COX3 SNCA HLA-DQB1 JPH3 C19ORF12 JPH3 PRKN ERCC4 APP UCHL1 CHCHD10 SPG21 SDHA
    Protein Mutations 1
    V158M
    SNP 0

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook